Skip to main content

Table 1 Clinical information on the GSE40272 prostate cancer cohort

From: Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer

Patient feature High ADAM19 (n) Low ADAM19 (n) Total (n)
All cases    77 (100 %)
 ADAM19 evaluated  36 (50.7 %)  35 (49.3 %) 71 (92.2 %)
Age at diagnosis    
 ≤54 7 (43.8 %) 9 (56.3 %) 16 (22.5 %)
 55-64 14 (45.2 %) 17 (54.8 %) 31 (43.7 %)
 ≥ 65 15 (62.5 %) 9 (37.5 %) 24 (33.8 %)
Cancer stage    
 II 4 (80 %) 1 (20 %) 5 (7 %)
 III 23 (46.9 %) 26 (53.1 %) 49 (69 %)
 IV 7 (47.7 %) 8 (53.3 %) 15 (21.1 %)
 Unknown 2 (100 %) 0 (0 %) 2 (2.8 %)
Gleason score    
 6 7 (47.7 %) 8 (53.3 %) 15 (21.1 %)
 7 26 (55.3 %) 21 (44.7 %) 47 (66.2 %)
 8 1 (33.3 %) 2 (66.7 %) 3 (4.2 %)
 9 1 (20 %) 4 (80 %) 5 (7 %)
 Unknown 1 (100 %) 0 (0 %) 1 (1.4 %)
PSA levels (ng/mL)    
 < 5 15 (45.5 %) 18 (54.5 %) 33 (46.5 %)
 5-6.9 12 (80 %) 3 (20 %) 15 (21.1 %)
 ≥ 7 7 (35 %) 13 (65 %) 20 (28.2 %)
 Unknown 2 (66.7 %) 1 (33.3 %) 3 (4.2 %)
Tumour recurrence    
 Yes 5 (29.4 %) 12 (70.6 %) 17 (23.9 %)
 No 29 (56.9 %) 22 (43.1 %) 51 (71.8 %)
 Unknown 2 (66.7 %) 1 (33.3 %) 3 (4.2 %)
  1. Clinicopathological features relative to ADAM19 mRNA expression levels in prostate tumours